Plasma Protein Therapeutics Global Market Report 2024

The plasma protein therapeutics market size has grown strongly in recent years. It will grow from $29.66 billion in 2023 to $32.22 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth observed in the historical period can be attributed to factors such as the increasing prevalence of rare diseases, a growing aging population, the expansion of the global blood plasma supply, a rise in hemophilia cases, advancements in diagnostic capabilities, and a supportive regulatory environment.

The plasma protein therapeutics market size is expected to see strong growth in the next few years. It will grow to $43.85 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be attributed to advancements in gene therapy, a rise in healthcare expenditure, expanded indications for therapies, the adoption of precision medicine approaches, and the implementation of patient access programs. Significant trends expected in the forecast period encompass technological innovations, the increased adoption of telemedicine, advancements in plasma fractionation technology, the development of next-generation therapies, the adoption of recombinant therapies, and a focus on personalized medicine approaches.

The growth of the plasma protein therapeutics market is anticipated to be driven by the increasing prevalence of autoimmune disorders. These conditions occur when the immune system mistakenly attacks and destroys healthy cells in the body. Therapeutic plasma exchange is a treatment used for autoimmune diseases, where the body misidentifies a part of itself as foreign, leading to the production of autoantibodies that attack the misidentified body part. According to a September 2021 report from Scientific American, autoimmune diseases affect approximately 4% of the global population. Consequently, the rising prevalence of autoimmune disorders is a significant factor fueling the growth of the plasma protein therapeutics market.

The growth of the plasma protein therapeutics market is expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting a year or longer and requiring ongoing medical care, significantly impact daily activities. Plasma protein therapeutics play a crucial role in managing chronic diseases by addressing deficiencies, modulating the immune system, and providing support for various physiological functions. According to the World Health Organization's data from September 2022, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million deaths globally each year. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this statistic. Therefore, the growing prevalence of chronic diseases is driving the growth of the plasma protein therapeutics market.

An emerging trend in the plasma protein therapeutics market is product innovation. Major companies in this sector are actively focused on introducing innovative products to gain a competitive edge. In November 2021, Biognosys, a Switzerland-based biotechnology company, launched a next-generation blood biomarker discovery solution. This service aims to help researchers understand the complexities of the blood proteome, facilitating unbiased discoveries for pharmaceutical and diagnostic development, as well as precision medicine. The unique features of Biognosys' Hyper Reaction Monitoring (HRMTM) technology and its optimized Liquid Chromatography-Mass Spectrometry (LC-MS) workflow set these solutions apart.

Strategic collaborations are playing a crucial role in the plasma protein therapeutics market. Major companies are entering partnerships to enhance their product portfolios, extend global reach, and drive innovation in new therapy development. For instance, LFB Plasma, a US-based plasma collection company, announced a collaboration with the Plasma Protein Therapeutics Association (PPTA) in September 2022. This strategic partnership is aimed at expanding LFB Plasma's presence in the US and reinforcing its commitment to both plasma donors and patients.

In April 2022, Grifols S.A., a Spain-based pharmaceutical and chemical manufacturer, acquired Tiancheng (Germany) Pharmaceutical Holdings AG for €1.6 billion ($1.72 billion). This acquisition is expected to accelerate and broaden Grifols' product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Tiancheng (Germany) Pharmaceutical Holdings AG, also known as Biotest, is a Germany-based healthcare company specializing in innovative hematology and clinical immunology, focusing on the development, manufacturing, and marketing of plasma proteins and biotherapeutic drugs.

Major companies operating in the plasma protein therapeutics market report are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, Shire plc, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., MP Biomedicals LLC, Biotest AG, Taibang Biological Group Co Ltd, Arthrex Inc., Johnson and Johnson, Abeona Therapeutics Inc., Octapharma Plasma Inc., Bayer AG, Bioverativ Inc., Grifols Biologicals Inc., Baxalta US Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood.

North America was the largest region in the plasma protein therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within plasma protein therapeutics include immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other related products. Immunoglobulin constitutes a component of blood plasma containing antibodies, and it is administered through various routes such as intravenous and subcutaneous. These treatments find applications in addressing conditions such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and various other medical needs.

The plasma protein therapeutics market research report is one of a series of new reports that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.